Cyprus vs Trinidad and Tobago: Average non-HDL cholesterol levels
Cyprus
3.5
in 2018
Trinidad and Tobago
3.5
in 2018
Cyprus rank
52nd
Trinidad and Tobago rank
52nd
Average non-HDL cholesterol levels over time
- Cyprus
- Trinidad and Tobago
How they compare
Cyprus currently reports 3.5 against 3.5 in Trinidad and Tobago, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Cyprus ahead.
Cyprus ranks 52nd and Trinidad and Tobago ranks 52nd of 191 countries.
Cyprus has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cyprus | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.2 | 3.5 | 0.7 | Cyprus |
| 1990s | 4.04 | 3.47 | 0.57 | Cyprus |
| 2000s | 3.79 | 3.42 | 0.37 | Cyprus |
| 2010s | 3.62 | 3.5 | 0.1222 | Cyprus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Cyprus or Trinidad and Tobago?
- Cyprus, at 3.5 against 3.5 in Trinidad and Tobago as of 2018.
- What is the difference in average non-hdl cholesterol levels between Cyprus and Trinidad and Tobago?
- 0, with Cyprus ahead.
- How many years of comparable data are there for Cyprus and Trinidad and Tobago?
- 39 years are reported by both, from 1980 to 2018.
- How do Cyprus and Trinidad and Tobago rank globally for average non-hdl cholesterol levels?
- Cyprus ranks 52nd and Trinidad and Tobago ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.